Search

Trust favourite Alnylam approaches key FDA decision Biotech trust stock favourite Alnylam Pharmaceuticals (Nasdaq:ALNY) should find out later this week whether the FDA will grant approval to its first product, Onpattro (patisiran), for hereditary transthyretin-mediated amyloidosis (or hATTR). In this case, unusually, there is relatively little concern that Onpattro may not receive US approval and the […]

Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a  US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]

Trust favourite  Biogen preps for detailed Alzheimer’s trial results Trust favourite Biogen (Nasdaq: BIIB), the largest single holding for Biotech Growth Trust (BIOG, 11.7% of NAV) and widely held stock among other sector specialist collective vehicles – will with its joint venture partner Eisai shortly disclose detailed results from a Phase II study of the […]

Celgene claims win for luspatercept in Believe trial Specialist trust favourite Celgene (Nasdaq: CELG) has reported positive result in a Phase III trial with the drug candidate luspatercept for treatment of anaemia associated with beta-thalassemia. This follows the company’s success in the Medalist Phase III trial win with the same drug in anaemia associated with myelodysplastic syndrome (MDS). The unambiguous […]

Key trust holding Biogen claims rare Alzheimer’s trial success Trust favourite Biogen saw its stock rise by 20% on Friday, after reporting a surprise apparently positive result from a Phase II study with the anti-amyloid beta protofibril antibody BAN-2401 in the notoriously tough indication of Alzheimer’s disease. However, the share price boost to Biogen probably reflects the implied […]

Autolus IPO boosts WPCT to top of specialist trust league in June The Nasdaq float of Autolus, one its top ten investee companies, boosted Woodford Patient Capital Trust (WPCT) to top position in the performance league table of biotech/healthcare specialist investment trusts for the month of June, both in terms of price and NAV total return. […]

Trust favourite Celgene claims win in Medalist trial US biotech and specialist trust favourite Celgene (Nasdaq: CELG) has reported a positive result in a closely-watched Phase III trial that was being seen as a key step necessary in its rehabilitation with investors. The trial was of the drug candidate luspatercept for treatment of anaemia associated with a type […]

Alexion files for key drug with priority review voucher Trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) yesterday confirmed it had made a US regulatory submission for approval of ALXN1210, its long-acting C5 complement inhibitor, for the treatment of the ultra-rare condition of paroxysmal nocturnal hemoglobinuria (PNH). Alexion is a cornerstone holding for both the OrbiMed-managed Biotech Growth Trust […]

WPCT still at bottom of bio specialist trust league in May Neil Woodford’s eponymous Patient Capital Trust (WPCT) has once again ranked at the bottom of the performance league table of biotech/healthcare specialist investment trusts maintained by Marten & Co in the month of May, both in terms of price and NAV total return. This is […]

HBM boosts dividend by 20% after stellar year London-listed HBM Healthcare (HBMN) has proposed a CHF 7/share dividend for year to end April, a 20% rise, after a strong year in which it saw a 11% rise in NAV and 34% rise in share price, beating the broadest biotech index and all other sector specialist […]